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Denaturing high-performance liquid chromatography (DHPLC), which has recently been 
developed as an automated method to detect mutations, is at least ten times less expensive 
than the direct sequencing method; however, its sensitivity and specificity for cardiac myo-
sin-binding protein C (MYBPC3) gene mutations in hypertrophic cardiomyopathy have not 
been reported yet.  A mutation analysis of exons 1 to 35 of MYBPC3 gene from 20 Japa-
nese patients with hypertrophic cardiomyopathy was performed using DHPLC and direct 
sequencing.  Compared to direct sequencing, the sensitivity and specificity of DHPLC 
were 87.5 % and 97.42 %, respectively.  Its positive and negative predictive values were 
41.18 % and 99.74 %.  The positive and negative likelihood ratios were 33.95 and 0.13, and 
the prevalence was 2.02 %.  DHPLC showed high sensitivity and specificity for detecting 
MYBPC3 gene mutations in hypertrophic cardiomyopathy.  The use of this complementary 
sequencing method should reduce the cost of detection of MYBPC3 gene mutations, and 
could be used to screen patients with hypertrophic cardiomyopathy.
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Genotyping of sarcomeric genes is currently used 
to identify mutations in patients with familial hy-
pertrophic cardiomyopathy; hence, it is essential 
to have an automatic, inexpensive, non-hazardous, 
highly sensitive and specific method for genetic 
analysis.  Hypertrophic cardiomyopathy is inher-
ited as a Mendelian-autosomal dominant trait and 
is caused by mutations in any of the 13 genes en-
coding proteins of the cardiac sarcomere and the 
non-cardiac sarcomeric protein (Seidman et al., 
2001; Richard et al., 2006).  In several studies, mu-
tations of the cardiac myosin-binding protein C gene 
(MYBPC3) were found to be one of the two most 
common genetic causes of familial hypertrophic car-
diomyopathy (Jääskeläinen et al., 2002; Erdmann et 
al., 2003; Mörner et al., 2003; Richard et al., 2003). 
To date, more than 150 mutations, consisting of mis-
sense, deletion/insertion and splice site abnormali-
ties, have been identified in MYBPC3. 
 Direct sequencing is the gold standard method 
for the detection of gene mutations, but it is labori-
ous, time consuming and expensive (Suzuki et al., 
2009).  Alternative mutation screening techniques 
may play a role in both candidate gene analysis and 
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diagnosis.  Ideally, a method to screen mutation in 
new samples should be sensitive, non-hazardous, 
relatively inexpensive and fully or at least semi-
automatic to minimize the time required for the 
test, labor and cost.  Denaturing high-performance 
liquid chromatography (DHPLC) has recently 
been developed as an automated method to detect 
mutations, and it is at least 10 times less expensive 
than the direct sequencing method (O’Donovan et 
al., 1998).  Therefore, it potentially overcomes the 
drawbacks of the direct sequencing method.  How-
ever, the sensitivity and specificity of DHPLC to 
detect MYBPC3 gene mutations in hypertrophic 
cardiomyopathy have not been reported yet.  In 
this study, we analyze MYBPC3 gene in patients 
with hypertrophic cardiomyopathy and asses the 
sensitivity and specificity of DHPLC by comparing 
them with those of the direct sequencing method. 
 
 
Subjects and Methods
 
The subjects were 20 Japanese patients diagnosed 
as having primary hypertrophic cardiomyopathy 
at Tottori University Hospital.  Briefly, clinical di-
agnostic criteria were adults with maximum myo-
cardium wall thickness of > 13 mm determined by 
echocardiography in the absence of any other con-
founding diagnosis.  Genomic DNA was extracted 
from peripheral white blood cells using the stan-
dard phenol-chloroform procedure.  Exons 1 to 35 
of the MYBPC3 gene were amplified by PCR using 
primers designed according to the published ge-
nomic sequences of MYBPC3 (Carrier et al., 1997). 
PCR products were run in 1% agarose gel, stained 
with ethidium bromide and visualized employing a 
UV transilluminator. 
 DHPLC analysis was performed using the 
Transgenomic WAVE system (Transgenomic, 
Omaha, NE) to detect genetic variants.  To obtain 
heteroduplexes with the WAVE system, the predic-
tion of temperature and gradient condition was de-
termined using the Stanford Genome Technology 
Center software (http://insertion.stanford.edu/melt.
html) and the WAVEMAKER software.  Three 
melting temperatures were chosen from the pre-
dictions.  Three types of samples were chosen for 
DHPLC, i.e., wild type as a control, samples from 
hypertrophic cardiomyopathy patients, and a mix 
of wild type and patient samples.  The heteroduplex 
peak resolve was influenced by the specific nucle-
otide mismatch present and the melting character-
istics of the surrounding bases.  Elution profiles 
that differed from wild type indicated the presence 
of mutation or polymorphism.  Normal samples 
were recruited for control (wild type) amplicon of 
DHPLC analysis from 5 healthy Japanese.  The 
sequencing was performed with the Abi Prism 373 
DNA Sequencer (Applied Biosystems, Foster City, 
CA) according the manufacturer’s instructions. 
This study has been approved by the Ethical Com-
mittee of Faculty of Medicine, Tottori University.
 The diagnostic test was based on a 2X2 con-
tingency table analysis to compare DHPLC and the 
sequencing method.  Since the sample amplicon 
of DHPLC and sequencing was a DNA fragment 
from each exon of the MYBPC3 gene, the sample 
unit which was used for statistical analysis was 
each exon of MYBPC3.  The estimated number of 
mutations of the MYBPC3 gene in hypertrophic 
cardiomyopathy is 1 mutation in each patient. 
Thirty three fragments of PCR product were ob-
tained from 35 exons of MYBPC3 (Fig. 1A).  Exon 
2 was amplified in 2 separated fragments.  Three 
separated fragments were obtained from 3 of 2 
short tandem exons.  They were exon 14–15, exon 
19–20 and exon 34–35.  Using the formula of single 
proportion, 12 positive signals of DNA amplicon 
were required in DHPLC, and the minimum total 
number of DNA amplicons was 369. 
 
 
Results and Discussion
 
All MYBPC3 exons were successfully amplified 
by PCR at 60˚C melting temperature (Fig. 1A). 
DHPLC was performed for MYBPC3 gene DNA 
from all 20 patients and 5 normal subjects.  Waves 
with 2 or more peaks in the amplicon from pa-
tient samples indicated a heterozygous mutation or 
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negative and 10 false positive were identified by 
DHPLC.  The sensitivity and specificity of DH-
PLC were 87.5 % and 97.42 %, respectively.  In 
Fig. 1. 
A: PCR amplification product of MYBPC3 gene from exon 1 to exon 35.  Exon 2 was amplified using 2 different primer 
sets; each of exons 14 and 15, 19 and 20, and 35 and 36 were amplified using one primer set.  All MYBPC3 exons were 
successfully amplified by PCR at 60˚C melting temperature. 
B: An example of DHPLC wave analysis from the same segment of amplified DNA.  Double-peak waves in the amplicon 
from a patient DNA sample indicated a heterozygous mutation or polymorphism, whereas, a wave with two or more 
peaks in the mix amplicon indicated a homozygous mutation or polymorphism. 
DHPLC, denaturing high-performance liquid chromatography; M, molecular weight marker.
Table 1.  Sensitivity and specificity of DHPLC 
versus sequencing
 Sequencing Sequencing Total
 (+) (–)
DHPLC (+) 7   10   17
DHPLC (–) 1 378 379
Total 8 388 396
DHPLC, denaturing high-performance liquid chromatog-
raphy.
Sensitivity = 87.5%, specificity = 97.42%, positive predic-
tive value = 41.18%, negative predictive value = 99.74%, 
positive likelihood ratio = 33.95, negative likelihood ratio 
= 0.13, prevalence = 2.02%.
19
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0
34
–3
5
14
–1
5
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1357—
603—
310—
bp  M 1 2a 2b 3  4 5 6 7 8 9 10 11 12 13 16 M 17 18 21 22 23 24 25 26 27 28 29 30 31 32 33
B Wild type
Sample from patient
Mix
Heterozygous Homozygous
polymorphism, whereas, in the mix amplicon they 
indicated a homozygous mutation or polymorphism 
(Fig. 1B).  We found more than one peak of the 
DHPLC wave at exon 5 of samples from both con-
trol subjects and patients indicating the probability 
of polymorphism. 
 Sequencing was performed for all DNA 
samples from the patients.  Consistent with the 
DHPLC result, we found a polymorphism in exon 
5 of MYBPC3 gene in samples from patients and 
normal subjects, and therefore, we excluded exon 
5 from the analysis of sensitivity and specificity of 
DHPLC versus sequencing.  Three hundred sixty 
nine DHPLC waves out of 660 were reliable for the 
analysis of sensitivity and specificity of DHPLC 
versus sequencing.  As shown in Table 1, one false 
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addition, its positive and negative predictive values 
were 41.18 % and 99.74 %, the positive and nega-
tive likelihood ratios were 33.95 and 0.13, and the 
prevalence was 2.02 %.
 Since a practical application of DHPLC ge-
netic analysis would be screening to reduce unnec-
essary sequencing, it is important that its sensitivity 
be the highest obtainable.  In several studies to 
detect mutations in various genes, the sensitivity 
of DHPLC consistently exceeded 96 % (Underhill 
et al., 1997; Liu et al., 1997-1998; Wagner et al., 
1999a, 1999b; Xiao et al., 2001).  The ability of 
DHPLC to detect a mutation depends upon the 
formation of heteroduplexes (Xiao et al., 2001; 
Rudolph et al., 2002); the mixed amplicon should 
be tested using various ratios.  For optimal muta-
tion detection, it was important to evaluate the PCR 
reaction and running profile.  In this study, we used 
Taq DNA polymerase for the PCR reaction and 
sequencing.  The sensitivity and specificity of DH-
PLC may be increased by using other polymerases 
which have higher fidelity.  This warrants further 
study.
 Identification of mutations in sarcomeric 
genes is meaningful for patients with hypertrophic 
cardiomyopathy.  Once a mutation is identified in a 
patient, screening of all family members is recom-
mended, particularly for those who have symptoms 
of cardiac disease.  For this reason, it is important 
to establish an inexpensive method that improves 
screening of MYBPC3 gene mutations in hypertro-
phic cardiomyopathy.
 Mutation analysis using sequencing is ex-
pensive because each exon is sequenced in both 
directions.  The cost per run, even in subsidized 
laboratories, is about US $10 to $25, excluding the 
costs of DNA isolation, PCR reagents and labor/time 
(O’Donovan et al., 1998; Xiao et al., 2001; Suzuki et 
al., 2004).  Any mutation screening must be techni-
cally simple, use inexpensive reagents, and be highly 
specific and highly sensitive.  Therefore, a muta-
tion screening method may contribute to reduce the 
number of unnecessary sequencing tests.  DHPLC is 
a relatively new method to detect mutations.  It is run 
automatically and it is relatively inexpensive.  Each 
amplicon of DHPLC is screened for about US $1.5 
(Wagner et al., 1999).  This inexpensive method can 
become affordable worldwide, particularly for early 
genetic diagnosis or gene mutation screening.
 Finally, we conclude that because of the high 
sensitivity and specificity of DHPLC regarding de-
tection of MYBPC3 gene mutations in hypertrophic 
cardiomyopathy, it should become a useful muta-
tion screening method for hypertrophic cardiomyo-
pathy. 
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